| __timestamp | Apellis Pharmaceuticals, Inc. | Catalyst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 4473654 |
| Thursday, January 1, 2015 | 6356782 | 8597010 |
| Friday, January 1, 2016 | 4303743 | 7910260 |
| Sunday, January 1, 2017 | 10463151 | 7304399 |
| Monday, January 1, 2018 | 22639184 | 15875961 |
| Tuesday, January 1, 2019 | 67046483 | 36881187 |
| Wednesday, January 1, 2020 | 139401000 | 44233754 |
| Friday, January 1, 2021 | 176771000 | 49628000 |
| Saturday, January 1, 2022 | 277163000 | 58183000 |
| Sunday, January 1, 2023 | 500815000 | 133710000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Apellis Pharmaceuticals and Catalyst Pharmaceuticals have shown distinct strategies in handling these costs. From 2014 to 2023, Apellis saw a staggering increase in SG&A expenses, growing by over 17,000%, peaking at $500 million in 2023. In contrast, Catalyst Pharmaceuticals maintained a more conservative growth, with expenses increasing by approximately 2,900% to $134 million in the same period.
This data suggests that while Apellis is aggressively investing in its operations, Catalyst is opting for a more controlled approach. Investors and industry analysts should consider these trends when evaluating the financial health and strategic direction of these companies. Understanding how each company manages its SG&A costs can provide insights into their operational efficiency and long-term sustainability.
Who Optimizes SG&A Costs Better? Pfizer Inc. or Catalyst Pharmaceuticals, Inc.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Catalyst Pharmaceuticals, Inc.
Insmed Incorporated or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Catalyst Pharmaceuticals, Inc.
Exelixis, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Veracyte, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared